Tyra Biosciences (TYRA) Cash from Investing Activities (2020 - 2026)
Quarterly Cash from Investing Activities fell 475.46% to -$120.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$79.8 million through Mar 2026, up 5.5% year-over-year, with the annual reading at $72.5 million for FY2025, 173.64% up from the prior year.
Tyra Biosciences filings provide 7 years of Cash from Investing Activities readings, the most recent being -$120.2 million for Q1 2026.
- Cash from Investing Activities hit -$120.2 million in Q1 2026 for Tyra Biosciences, down from $34.4 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $34.4 million in Q4 2025 and bottomed at -$145.0 million in Q2 2024.
- Average Cash from Investing Activities over 5 years is -$17.1 million, with a median of -$43000.0 recorded in 2023.
- The largest annual shift saw Cash from Investing Activities plummeted 687700.0% in 2023 before it soared 44180.49% in 2024.
- Tyra Biosciences' Cash from Investing Activities stood at -$21000.0 in 2022, then plummeted by 687700.0% to -$144.4 million in 2023, then surged by 104.82% to $7.0 million in 2024, then soared by 394.06% to $34.4 million in 2025, then tumbled by 449.78% to -$120.2 million in 2026.
- Per Business Quant, the three most recent readings for TYRA's Cash from Investing Activities are -$120.2 million (Q1 2026), $34.4 million (Q4 2025), and -$14.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -428.90 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Tyra Biosciences | 2.03 Bn | 2.03 Bn | - | -120.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120.24 Mn |
| Mar 31, 2026 | -120.24 Mn |
| Dec 31, 2025 | 34.38 Mn |
| Dec 31, 2025 | 34.38 Mn |
| Sep 30, 2025 | -14.81 Mn |
| Sep 30, 2025 | -14.81 Mn |
| Jun 30, 2025 | 20.87 Mn |
| Jun 30, 2025 | 20.87 Mn |
| Mar 31, 2025 | 32.03 Mn |
| Mar 31, 2025 | 32.03 Mn |
| Dec 31, 2024 | 6.96 Mn |
| Dec 31, 2024 | 6.96 Mn |
| Sep 30, 2024 | 21.56 Mn |
| Sep 30, 2024 | 21.56 Mn |
| Jun 30, 2024 | -144.99 Mn |
| Jun 30, 2024 | -144.99 Mn |
| Mar 31, 2024 | 18.07 Mn |
| Mar 31, 2024 | 18.07 Mn |
| Dec 31, 2023 | -144.44 Mn |
| Dec 31, 2023 | -144.44 Mn |
| Sep 30, 2023 | -83,000.00 |
| Sep 30, 2023 | -83,000.00 |
| Jun 30, 2023 | -43,000.00 |
| Jun 30, 2023 | -43,000.00 |
| Mar 31, 2023 | -41,000.00 |
| Mar 31, 2023 | -41,000.00 |
| Dec 31, 2022 | -21,000.00 |
| Dec 31, 2022 | -21,000.00 |
| Sep 30, 2022 | -48,000.00 |
| Sep 30, 2022 | -48,000.00 |
| Jun 30, 2022 | -251,000.00 |
| Jun 30, 2022 | -251,000.00 |
| Mar 31, 2022 | -239,000.00 |
| Mar 31, 2022 | -239,000.00 |
| Dec 31, 2021 | -105,000.00 |
| Dec 31, 2021 | -105,000.00 |
| Sep 30, 2021 | -240,000.00 |
| Sep 30, 2021 | -240,000.00 |
| Jun 30, 2021 | -240,000.00 |
| Jun 30, 2021 | -240,000.00 |
| Mar 31, 2021 | -60,000.00 |
| Mar 31, 2021 | -60,000.00 |
| Dec 31, 2020 | -67,000.00 |
| Dec 31, 2020 | -67,000.00 |